Exosomes: New Tuberculosis Biomarkers – Prospects From the Bench to the Clinic by Nicole A. Kruh-Garcia et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
19 
Exosomes: New Tuberculosis Biomarkers – 
Prospects From the Bench to the Clinic 
Nicole A. Kruh-Garcia1, Jeff S. Schorey2 and Karen M. Dobos1 
1Colorado State University  
2University of Notre Dame 
USA 
1. Introduction 
Biomarkers, derived from either the host (e.g. immunological markers, such as cytokines) or 
infectious agent (e.g. exported products, such as lipoarabinomannan), are indicative not 
only of disease but also of disease stage, severity and drug failure. Discovering new 
biomarkers from easily attainable bodily fluids is essential if we are to control tuberculosis, a 
diseases that kills 1.5 to 2 million individuals a year. The ideal biomarker could be used in 
the diagnosis and prognosis of disease from any suspect patient regardless of age, immune 
status or vaccination history. One potential biomarker source is exosomes; small membrane-
bound vesicles released from cells which can be found circulating in the blood, and can be 
readily harvested for diagnostic testing. Exosomes shed from Mycobacterium tuberculosis 
(Mtb) infected samples (from in vitro produced to in vivo models and clinical samples) could 
provide an ideal reservoir of tuberculosis biomarkers. While it is possible to detect and 
monitor host and other bacterial components on exosomes, the scope of the following 
experiments are focused specifically on the Mtb proteins that are incorporated into 
exosomes. 
1.1 Detection of tuberculosis 
New diagnostic measures for the detection of tuberculosis are needed to identify and 
distinguish individuals with active tuberculosis from those harboring the dormant Mtb 
bacillus. The established method of TB detection for over seventy years is the tuberculin skin 
test (TST) or Mantoux test. This approach monitors the presence and diameter of induration 
as an indicator of the delayed-type hypersensitivity reaction to an intradermal injection of 
purified protein derivative (PPD) of Mtb. Despite its worldwide use, there are several 
fundamental problems with the TST. First, while it can be used as an indicator of both the 
active disease and the asymptomatic, latent tuberculosis infection (LTBI), the test cannot 
differentiate between the two. Second, false positive results are frequent, most commonly 
due to a history of Bacille Calmette Guérin (BCG) vaccination. Similarly, due to the 
dominance of several conserved heat-shock protein in PPD, and their influence on the 
antigenicity of PPD (Yang, Troudt et al.), there is frequent cross-reactivity between 
infections with nontuberculosis mycobacterium (NTM) species (such as M. avium). Most 
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disconcerting are false negative readings typically associated with impaired immune 
function (attributed to infections with HIV or with drug use).  
The development of the interferon-gamma release assay (IGRA) has addressed some of the 
problems associated with the TST. Two types of IGRA test are currently commercially 
available, QuantiFERON-TB (Cellestis Limited) and T-SPOT-TB (Oxford Immunotec). Both 
measure the host biomarker, interferon-gamma (INF-) in whole-blood after stimulation 
with the mycobacterial antigens ESAT-6 and CFP10, by either ELISA or ELISpot assay, 
respectively. The T-SPOT-TB appears to be the most comprehensive diagnostic test to date 
(Table 1). Lastly, the Xpert MTB/RIF assay (Cephid) is a nucleic acid amplification based 
diagnostic and has the advantage of identifying resistance to rifampicin. However, since 
none of the aforementioned tests can distinguish between active and latent infections, 
sputum collection followed by microscopy (AFB smear) and culture, as well as chest 
radiography must be performed. The AFB smear test is simple, cost-effective and achieves 
high specificity; however this test suffers from a lack of sensitivity as on average it only 
detects 50% of active TB patients and even less in HIV positive patients and children.  
Test 
Detects 
active 
TB 
Detects 
latent 
TB 
Distinguishes 
between 
active and 
latent TB 
Distinguishes 
between BCG 
vaccination 
and Mtb 
infection 
Distinguishes 
between Mtb 
and NTM 
infection 
Reliable 
results in 
immune-
compromised 
patients? 
AFB Smear Yes No Yes Yes No Yes1 
AFB 
culture 
Yes No Yes Yes Yes Yes1 
TST Yes Yes No No No No 
Quanti-
FERON 
Yes Yes No Yes Yes 2 3 
T-SPOT-TB Yes Yes No Yes Yes 2 Yes 
Xpert 
MTB/RIF 
Yes Yes 3 Yes Yes Yes 
Clearview 
TB ELISA 
Yes No Yes  No Yes 
1Provided that sputum can be obtained. 
2This method can discriminate between most NTM (exceptions are M. gordonae, M. kansasii, M. szulgai 
and M. marinum); but it cannot distinguish between other members of the Mtb complex (M. bovis, M. 
africanum, M. microti and M. canetti). 
3Data is limited. 
Table 1. Comparison of a sampling of tuberculosis detection methods.  
The ideal diagnostic would minimize false positives due to BCG vaccination and infections 
with NTM, eliminate false negatives associated with the immunocompromised and be able 
to distinguish between active and latent infections while permitting increased case detection 
via a robust, cheap, fast and sensitive assay for its use in high-burden, low-income countries. 
According to the World Health Organization (WHO), there were 9.4 million new cases of 
active tuberculosis (TB) with a prevalence of 14 million cases in 2009, which accounted for 
about 1.7 million deaths (WHO 2010). A serious issue is the inaccuracy of these estimations, 
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with case detection rates (CDR) of only 63% (even lower in Africa) of pulmonary and other 
forms of the disease which is primarily due to undiagnosed and unreported cases (WHO 
2010). Of those individuals newly infected with Mtb, greater than one-tenth involved co-
infection with HIV. Uncovering LTBI in at-risk individuals (e.g.. HIV positive, household 
contacts, those on immunosuppressive drugs) is critical so that the proper medical 
treatments can be administered to prevent future activation of the disease. Expeditious 
detection of smear negative cases, of which there were an estimated 2 million instances 
(WHO 2010), could potentially allow for treatment 4-6 weeks sooner.  
1.2 Identifying diagnostic biomarkers of TB 
There are two major classes of biomarkers – host response and pathogen generated. The 
majority of the research being conducted focuses on host biomarkers – including INF- (as 
measured through the IGRA kits), other immunological markers (e.g.. cytokines, like IL-6 
and TNF), host protein profiling, as well as, the production of antibodies to dominant Mtb 
antigens (such as, malate synthase and MPT51 (Wanchu, Dong et al. 2008)) (Walzl, Ronacher 
et al.). One of the primary concerns with using immune response as biomarkers of disease is 
the variation observed among the patient population due to numerous factors including 
secondary disease (causing increased/decreased inflammation) and altered response due to 
drug therapy. Alternatively, products made and released by Mtb during infection can also 
serve as biomarkers. Bacterial molecules including DNA (Cannas, Goletti et al. 2008) and 
lipoarabinomannan (LAM) (Minion, Leung et al.) can both be detected in urine during 
infection. Unlike most immunological biomarkers, bacterial products are specific to the 
tuberculosis. Moreover, identification and quantification of multiple Mtb products 
secreted/released during infection has the potential to be developed into a multiplex assay. 
Further, by monitoring changes in a panel of biomolecules, one could generate a fingerprint 
that could be used to indicate the different stages of disease (such as active versus latent). 
To identify a combination of novel biomarkers for the generation of a point-of-care 
diagnostic test, we have begun screening human exosomes as a source of Mtb proteins. 
Preliminary data has proven that these vesicles are an untapped supply of pathogen derived 
biomarkers. There are several advantages to using exosomes: first, they can be isolated in a 
facile and expeditious manner. Second, they can be harvested from blood and urine – which 
is beneficial when sputum collection is not feasible (from children or in MDR cases). Third, 
our data indicates that Mtb proteins are not only contained, but also concentrated in these 
vesicles – allowing for greater sensitivity than can be achieved using unpurified whole 
blood or urine.  
1.3 Exosomes: Initial discoveries 
Exosomes were first described in mid-1980’s by Johnstone et al. and Stahl et al. in reference 
to the small vesicles that bud from reticulocytes during maturation (Harding, Heuser et al. 
1984; Johnstone, Adam et al. 1987). It was hypothesized that this process, was required to 
remove membrane-bound proteins such as the transferrin receptor from the maturing 
reticulocyte as these cells lack the lysosomes for protein degradation (Pan and Johnstone 
1983). In a series of elegant electron microscopy studies, it was determined that the 
transferrin receptor (TR) was endocytosed and trafficked to the MVB where it was observed 
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on ~50 nm interluminal vesicles. MVBs containing the TR were shown to fuse with the 
plasma membrane and release the interluminal vesicles  (Pan, Teng et al. 1985). These 
released vesicles were called exosomes.  
Additional studies have shown that exosome release is not specific to maturing 
reticulocytes, as they are constitutively shed from most mammalian cells types including B-
cells, macrophages and dendritic cells (Raposo, Nijman et al. 1996). Exosomes can be readily 
obtained from most bodily fluids, including but not limited to urine, plasma, breast milk, 
bronchoalveolar lavage (BAL) fluid and saliva (Admyre, Grunewald et al. 2003; Pisitkun, 
Shen et al. 2004; Caby, Lankar et al. 2005; Admyre, Johansson et al. 2007; Ogawa, Kanai-
Azuma et al. 2008) Exosomes released from antigen presenting cells contain MHC-I and 
MHC-II as well as CD86 and therefore are capable of antigen presentation (Zitvogel, 
Fernandez et al. 1999). Interestingly, exosomes derived from tumor cells have also been 
shown to induce an anti-tumor immune response, implicating a future utility in vaccine 
development (Zitvogel, Regnault et al. 1998).  
1.4 The advent of exosomes in tuberculosis research 
The Mtb cell wall is composed of a myriad of proteins and lipids, including the highly 
studied glycolipid, LAM. This molecule has been shown to be readily liberated from the 
mycobacteria during infection and has been correlated with several immunomodulatory 
functions (such as interactions with TLRs (Bhatnagar and Schorey 2007)). Beatty et al was 
the first to recognize LAM accumulation in MVBs and this report is consistent with 
subsequent exosomal release from infected cells (Beatty, Rhoades et al. 2000). Building upon 
initial evidence, Schorey et al characterized exosomes released from BCG-infected 
macrophages. Flow cytometry allowed for the identification of vesicles positive for MHC-II, 
Hsp70, and LAMP1, as well as mycobacterial pathogen-associated molecular patterns 
(PAMPs) (Bhatnagar, Shinagawa et al. 2007; Giri and Schorey 2008). They went on to 
demonstrate the exosomes released from mycobacterial-infected macrophages could 
activate both the inate and acquired immune responses in vitro and in vivo (Blood, 2007 and 
PLoS One 2008). In addition, it was shown that exosomes isolated from the BAL fluid of M. 
bovis BCG infected mice contained LAM and the 19kDa antigen (Bhatnagar, Shinagawa et al. 
2007).  
1.5 Concentration and siphoning of biomarkers in exosomes 
Exosome biology is a relatively new field with roughly 1000 primary journal articles and 
over 200 reviews (Raimondo, Morosi et al. 2011). Exosomes have been studied with 
techniques such as western blotting, microscopy, FACS and mass spectrometry. 
Characterization of exosomal contents, resulted in the identification of a number of host, as 
well as pathogen derived products, including:  lipids (Laulagnier, Motta et al. 2004) and 
nucleic acids (miRNA and mRNA) (Valadi, Ekstrom et al. 2007), in addition to proteins. 
However, only a few of these studies utilize proteomics to decipher the contents of these 
vesicles and their relationship to various diseases, such as cancers, diabetes, prenatal 
disorders and renal diseases (Ben Ameur, Molina et al. 2010; Diaz, Pinto et al. 2011; Moon, 
You et al. 2011). Proteomics was performed on purified exosomes as early as 2004 (Bard, 
Hegmans et al. 2004). Defining the proteomic content of exosomes derived from urine and 
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blood has been key to biomarker discovery in several diseases (Bard, Hegmans et al. 2004; 
Mears, Craven et al. 2004; Thomas, Sexton et al. 2010). However, the mining of exosome-
derived proteins related to infectious diseases has yet to be exploited. The discovery that 
mycobacterial products could be found in exosomes release from infected animals led to the 
first full-scale attempt to characterize the Mtb exo-proteome (comprehensive collection of 
proteins capable of being secreted from Mtb-infected cells within exosomes) (Giri, Kruh et 
al. 2010). The objective of this research is to fuel biomarker discovery utilizing mass 
spectrometry based approaches.  
2. The Mtb exo-proteome: in vitro 
Based on the hypothesis that exosomes are a novel source of bacterial components which 
could be exploited for biomarker identification, we set out to define the mycobacterial 
proteins contained in exosomes released from Mtb-infected macrophages. Exosomes were 
purified from Mtb infected macrophages using differential centrifugation and sucrose 
gradient (Griffiths, Heesom et al. 2007; Giri, Kruh et al. 2010). The exosomes contained the 
characteristic size and shape as defined by EM (Figure 1).  
             
Fig. 1. Electron micrograph of exosomes purified from Mtb infected J774a.1 cells at (A) 3000x 
(bar = 0.5 m) and (B) 8000x magnification (bar = 0.1 m). The vesicles showed the size (30 – 
100 nm) and spherical or cup-like shape expected of exosomes. 
2.1 Proteomics of exosomes released from Mtb-infected macrophages 
Consistent with previous publications (Bhatnagar, Shinagawa et al. 2007), the host exosomal 
marker LAMP-1, as well as mycobacterial LAM and 19 kDa antigen (Rv3763) were detected 
via western blot (data not shown). Several known secreted proteins previously undetected 
in exosomes, including KatG (Rv1908c), the Ag85 complex (Rv3804c, Rv1886c and Rv0129c), 
GroES (Rv3418c) and CFP10 (Rv3874), were also demonstrated by western blot analysis 
(Giri, Kruh et al. 2010). In addition to these proteins, we identified roughly forty 
mycobacterial proteins by MS, of which 95% were previously defined either experimentally 
or through predictive algorithms to be secreted (Table 2) (Rosenkrands, King et al. 2000; 
Malen, Berven et al. 2007; Giri, Kruh et al. 2010). One can hypothesize that the mycobacterial 
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proteins released into the phagosome or cytoplasm are transported to an MVB, incorporated 
into the interluminal vesicles and released from the infected cell via exosomes into various 
bodily fluids (Figure 2). As indicated earlier, the exosomes containing both host and 
mycobacterial components can modulate the host immune response. Similar experiments 
were performed with irradiated (dead) Mtb and only 1 mycobacterial protein was identified. 
Whether this difference between live and dead Mtb was due to differential transport of the 
mycobacteria within the macrophage or a requirement for mycobacterial metabolic activity 
requires further investigation.  
 
Fig. 2. Hypothesized pathway of exosome secretion in Mtb-infected cells. Based on 
experimental evidence, antigenic proteins are secreted within the Mtb-containing host 
compartment, packaged and shuttled into multivesicular bodies. The MVBs can fuse with 
the plasma membrane to release the exosomes into the peripheral fluids. 
In addition, J774a.1 macrophages were exposed to culture filtrate proteins (CFP), a complex 
mixture of over 200 proteins secreted from Mtb during in vitro growth (Sonnenberg and 
Belisle 1997). Exosomes released during this experiment were collected and analyzed after 
in-gel digestion. The mycobacterial proteins identified from the CFP-treated exosomes 
included many well-characterized immunedominant antigens and were remarkably similar 
(>85%) to those isolated from J774a.1 cells infected with live Mtb. As previously mentioned, 
exosomes are being evaluated as tumor vaccines and the presence of highly antigenic 
mycobacterial proteins on exosomes from CFP-treated macrophages suggests that they too 
may be a viable vaccine candidates for TB. This hypothesis is presently under investigtion.  
These aforementioned in vitro experiments afforded us with enough exosomal material to 
build our methodology and lay the foundation for the analysis of exosomes isolated from 
Mtb-infected mice, where samples more limited. In prior studies of exosomes, mycobacterial 
proteins were identified only by western blot. However, mass spectrometry allows for the 
identification of proteins without the use of antibodies (which are only available to a small 
subset of proteins). Moreover, while ~8 µg of exosomes is required for each western blot 
(identifying only one protein per blot), a parallel sample subject to MS analysis, allows for 
the discrimination of hundreds of proteins of both host and bacterial origin.  
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 Rv # Protein Name 
Relative 
Abundance (%) 
Rv2220 GlnA1 13.05 
Rv1860 Mpt32/APA 12.34 
Rv1886c Antigen 85-B 9.58 
Rv3804c Antigen 85-A 8.92 
Rv1980c Mpt64 6.89 
Rv1908c KatG 4.43 
Rv3418c GroES 3.59 
Rv0934 PstS1 3.41 
Rv3248c SahH 3.17 
Rv0462 LpdC 2.87 
Rv1926c Mpt63 2.46 
Rv1355c MoeY 2.22 
Rv2244 AcpM 2.16 
Rv2031c HspX 1.86 
Rv1932 Cfp20 1.80 
Table 2. Sampling of proteins identified in exosomes from H37Rv-infected J774a.1 cells by 
LC-MS-MS. See Giri, Kruh et al. 2010, for the extended list. The fifteen most abundant 
mycobacterial proteins are listed, based on the total number of spectral counts from both in-
solution and in-gel processing (compiled in the aforementioned paper plus additional 
unpublished experiments). Relative abundance was calculated using the following formula: 
(total # of spectral counts for a given protein/cumulative total # of mycobacterial spectral 
counts) * 100. 
The primary analysis from in vitro derived exosomes, provides an extended candidate list 
for the study of Mtb biomarkers. Our next step in the biomarker discovery pipeline is to 
verify that these results translate to an in vivo system. 
3. The Mtb exo-proteome: in vivo 
Since tuberculosis is primarily a respiratory affliction, the initial in vivo investigation was 
performed utilizing exosomes isolated from BAL fluid to determine if mycobacterial 
proteins could be identified from an infected animal model. The hypothesis is that the 
protein composition of BAL fluid exosomes will reflect the initial in vitro findings and the 
proteins identified will change over the course of the infection. This may provide the 
starting point for making correlations between exosomal content and stage of infection. 
The end goal is find “peptide fingerprints” which represent the mycobacterial proteins 
most commonly present in exosomes of patients with active or latent tuberculosis. 
3.1 Proteomics of exosomes released into the bronchoalveolar lavage fluid of Mtb-
infected mice 
BAL fluid was collected from mice infected via aerosol with either wild-type (H37Rv) or a 
relA deficient mutant of Mtb. Both the concentration and Mtb protein content of the 
exosomes were monitored over time. To accomplish this, we employed similar MS 
methodology as in our in vitro analysis (Giri, Kruh et al. 2010). MS analysis of BAL fluid 
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derived exosomes from H37Rv Mtb-infected mice over the different time points revealed a 
significant overlap (50%) with the mycobacterial proteins previously identified in the in vitro 
tissue culture experiments (Figure 3). No mycobacterial proteins were identified in 
exosomes purified from BAL fluid on day 1 post-infection or as expected, in naïve mice. In 
all other time points, the number of mycobacterial spectral counts (data not shown) as well 
as the proteins identified changed over time (Figure 4). In exosomes from both H37Rv and 
the relA mutant infections, the largest number of proteins were identified early in the 
infection (day 14), however the number of proteins identified from the relA mutant was half 
that of the wt strain. Interestingly, during the wt infection, the exosomes that yielded the 
highest total mycobacterial spectral count was at day 56. Moreover, the exosomes from wt-
infected mice showed on average three times as many spectral counts per time point than 
the relA mutant (data not shown). This is likely, at least in part, due to the differences in 
bacterial load between wt and ∆RelA-infected mice (10 to 100 fold difference in lung colony 
forming units at different time points). In both wt and ∆RelA-infected mice there were some 
proteins present on exosomes which were there throughout the course of disease, while 
others were transiently expressed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Venn diagram depicting the number of mycobacterial proteins identified in exosomes 
from H37Rv-infected macrophages (yellow), the BAL fluid of H37Rv-infected mice (blue), 
and both (overlap). 
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Fig. 4. CFUs versus Mtb proteins identified over time in (A) H37Rv Mtb-infected mice and 
(B) ∆RelA-infected mice. The red lines indicate the Log CFU in the lung over time, as 
indicated on the right y-axius. CFUs are representative of the bacterial load of the lungs of 5 
mice per time point. The ble line represents the number of proteins identified by MS over 
the course of the infection, as measured on the left y-axis. 
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While majority of the 15 most dominant mycobacterial proteins found in exosomes released 
from infected J774a.1 cells were seen in the mouse exosomes (Table 3), many of them were 
less abundant (e.g.. KatG, SahH and Cfp20) and several of these proteins were absent 
entirely (e.g. LpdC and MoeY). Most interesting are several striking differences in the 
mycobacterial protein identified on exosomes from BALfluid when mice were infected with 
wt or relA mutant. The relA gene is annotated as being a non-essential gene, based on 
viability of the strain subsequent to the insertion of the Himar1 transposon (Lamichhane, 
Zignol et al. 2003). Biochemical characterization of the RelA protein suggests that this 
enzyme has both 3’-pyrophosphoryltransferase and pyrophosphohydrolase activities. 
Functional deletion of this protein results in the depletion of hyperphophorylated guanosine 
((p)ppGpp), which can decrease protein synthesis leading to effects on long term growth 
and the ability to transition in and out of dormancy (Avarbock, Salem et al. 1999; Primm, 
Andersen et al. 2000; Klinkenberg, Lee et al. 2010). Dahl et al. has reported that the gene 
expression level of several secreted proteins (including the Antigen 85 complex and GroES) 
are increased in the relA mutant (Dahl, Kraus et al. 2003), however, based on spectral counts, 
the majority of the secreted proteins identified in exosomes display the opposite trend 
(Figure 5). While a more quantitative approach is necessary to truly hone in on the 
differences between the wt and relA mutant, this preliminary data suggest that there is a 
qualitative and quantitative difference in proteins targeted to MVB/exosomes when 
macrophages are infected with wt compared to relA mutant in vivo. Future experiments, 
including multiple reaction monitoring (MRM)-MS analysis will allow for the monitoring of 
the intensity of specific peptides in each sample, while allowing one to ignore the m/z’s 
corresponding to host peptides. 
Rv # Protein Name 
Day
14 
Day 
28 
Day 
56 
Day 
112 
Rv2220 GlnA1 + * * * 
Rv1860 Mpt32/APA + * * ∆ 
Rv1886c Antigen 85-B + + + + 
Rv3804c Antigen 85-A + + + + 
Rv1980c Mpt64 + + + * 
Rv1908c KatG * * * - 
Rv3418c GroES + + * * 
Rv0934 PstS1 + + * - 
Rv3248c SahH * + * - 
Rv0462 LpdC - - - - 
Rv1926c Mpt63 * + * - 
Rv1355c MoeY - - - - 
Rv2244 AcpM + + + ∆ 
Rv2031c HspX + + + * 
Rv1932 Cfp20 * * * - 
Table 3. Comparison of the fifteen most abundant proteins originally identified in exosomes 
from H37Rv-infected J774a.1 cells (Table 2) to their presence (+) or absence (-) in BAL fluid 
exosomes at various time-points during the infection of Balc/c mice. + = protein detected in 
both H37Rv and relA mutant exosomes; * = presence in H37Rv exosomes only; ∆ = only in 
relA mutant exosomes.  
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Fig. 5. Kinetics of various proteins during the course of the wild-type H37Rv (blue) 
compared to the relA mutant (red) infection, including GlnA, Antigen 85-A, HspX and 
Mpt63. These graphs emphasize the range of spectral counts and the pattern of individual 
protein expression. Transposon mutants effecting the expression of most of these proteins 
have led to the hypothesis that many of these proteins (HspX, Ag-85a, Mpt63) are “non-
essential” (Sassetti, Boyd et al. 2003) – but their presence in exosomes is an indicator that 
their expression may be triggered during infection (HspX, as seen by transcipts (Hu, 
Mangan et al. 2000; Dubnau, Fontan et al. 2002) and not in a simple culture. 
4. Conclusions: Future of biomarkers in tuberculosis 
Tuberculosis research in diagnostics has suffered from a lack of resources for the discovery 
and down-stream development of a cheap and facile clinical assay for the detection of active 
TB and to distinguish active from latent infection. This is due in part to the reliance on the 
TST; which for decades provided a cheap assay for detection of Mtb infection, and by our 
reliance on sputum smear tests to detect active disease. Most would argue that neither are 
optimal means to detect and diagnose TB nor evaluate drug treatment. However, in the 
absence of assays that could replace these tests without increases in cost, these remain the 
gold standard. The Mtb proteome has been mined for decades in pursuit of a serodiagnostic 
or celluar assay for tuberculosis, and the development and use of IGRA tests represent a 
hallmark of success. The outlook for a serodiagnostic assay appears more dismal, due to the 
requirement of either a predictable antibody response or high bacterial product shedding 
into the blood or BAL fluid. Our initial identification of Mtb proteins in BAL fluid exosomes 
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was a stepping-stone in the process of novel discovery of resources for development of 
second-generation diagnostic and prognostic assays. While BAL fluid is not the most ideal 
fluid to collect from patients, its isolation from mice and the use of it in the discovery phase 
of biomarker identification is suitable if these Mtb exo-proteome findings translate to other 
bodily fluids. Exosomes can be isolated from urine and serum, both of which are easier to 
collect than sputum. Harvesting and characterization of sera and urine exosomes are 
commonplace in diseases such as cancer. Consistent with our findings in the mouse model, 
our preliminary evidence from a panel of five TB patients and five household contacts 
suggests that sera analyzed from patients with active disease contain on average over 3000 
µg of exosomes per mL, which is over 30 times greater than the concentration of exosomes 
in the control sera. This makes exosomes an attractive target for pathogen-associated 
diagnostic biomarkers. Since many diagnostics are unreliable in immune compromised 
individuals, the allure of an exosome-based diagnostic will be enhanced if the exosomes 
undergo a similar rise in individuals co-infected with HIV.  
Bodily fluids such as urine and blood are highly complex (with an estimate of >106 protein 
products in human plasma (Anderson and Hunter 2006)). The purification of exosomes from 
these samples reduces the amount of biocomponents resulting in a drastic enrichment. 
Numerous attempts have been made using MS to search for mycobacterial proteins in whole 
blood or urine. Unfortunately the results from these studies were not encouraging as even 
immunodepletion (with a MARS column) and various fractionation techniques (e.g. SCX 
and mRP on an HPLC), did not lead to the identification of a significant number of 
mycobacterial proteins in blood or urine. One major benefit to isolating exosomes from these 
fluids prior to proteomic studies is that these vesicles not only serve as a mechanism of 
concentrating the mycobacterial proteins, but they are also an effective method of removing 
major contaminants found in bodily fluids. 
Urine is an established, readily attainable source of exosomes (Pisitkun, Shen et al. 2004). As 
previously mentioned, LAM (and mycobacterial DNA) has been found in urine of Mtb-
infected patients, including those with HIV. One kit currently on the market for the 
detection of LAM in urine is the Clearview TB ELISA (Inverness Medical Innovations Inc.). 
How LAM is secreted into the urine is questionable, however one can hypothesize that 
transport from the site of infection into the urine can occur through exosomes – either by 
encapsulation or incorporation into the lipid membrane of the vesicle. It is possible that 
LAM could be an additional marker in combination with Mtb proteins in a future clinical 
assay. Although at this point, like all proteins identified in exosomes, the concentration of 
LAM per volume of exosome would need to be quantified at various time-points during 
infection. 
The discovery phase of identifying biomarkers from exosomes is in its infancy. While we 
have the potential to study fluctuations in exosomal host proteins too, deciphering these 
differences can be tricky due to additional changes in immune response and reactions to 
secondary infections or inflammatory disease. In the end, the best diagnostic may involve 
monitoring numerous proteins, perhaps both host and pathogen derived. The content of 
exosomes has the potential not only for use in diagnostics, but also additional predictive 
value in the classification of disease status, assessment of therapeutics and overall 
prognosis. 
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The use of quantitative proteomics and MRM technology will be key in narrowing down the 
list of candidates. While this method is not necessarily suitable for the clinical lab (especially 
those in resource-limited areas) or is it cost effective – it is a mechanism to define biomarkers 
that can be implemented in a more cost effective diagnostic tool, such as an ELISA, or micro-
fluidic “dip-test” that could be performed in a resource poor setting. 
Another important consideration is the method used for exosome purification. At present 
the gold standard calls for differential centrifugation followed by sucrose gradient. 
Although this results is highly purified exosomes it is not suitable for high throughput 
analysis of serum/urine samples and cannot be used in the setting where TB diagnostics is 
most needed. Recently there have been a number of new purification techniques that have 
been developed include microfiltration using low protein-binding size exclusion filters, size-
exclusion chromatography, and microfluidics. ExoQuickTM, a recently developed 
commercial product from System Biosciences, allows for rapid isolation of exosomes based on 
a simple precipitation process and shows promise as a purification technique amenable to a 
point-of-care diagnostics.  
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